Source-grounded facts extracted from Voyager Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Voyager Therapeutics, Inc.: Increased authorized capital stock from 125,000,000 to 245,000,000 shares and common stock from 120,000,000 to 240,000,000 shares (effective 2026-06-09).
“the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 9, 2026”
Voyager Therapeutics, Inc. shareholders approved Amendment to Fifth Amended and Restated Certificate of Incorporation to increase authorized shares of capital stock from 125,000,000 to 245,000,000 and authorized shares of common stock from 120,000,000 to 240,000,000.
“Voyager’s stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company’s capital stock from 125,000,000 shares to 245,000,000 shares and increase the number of authorized shares of common stock from 120,000,000 shares of common stock to 240,000,000 shares of common stock. The results of the stockholders’ vote with respect to such proposal were as follows: For Against Abstain Broker Non-Votes 43,464,491 2,593,426 108,424 -”
Voyager Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
“Voyager’s stockholders ratified the appointment of Ernst & Young LLP as Voyager’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain Broker Non-Votes 45,902,883 108,561 154,897 -”
Voyager Therapeutics, Inc. shareholders approved Non-binding advisory proposal regarding compensation of named executive officers.
“Voyager’s stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager’s named executive officers. The results of the stockholders’ vote with respect to such proposal were as follows: For Against Abstain Broker Non-Votes 32,041,373 910,087 157,037 13,057,844”
Voyager Therapeutics, Inc. shareholders approved Election of Class II directors.
“Voyager’s stockholders elected James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D., each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until such nominee’s successor has been duly elected and qualified, subject to such nominee’s earlier death, resignation, or removal. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes James A. Geraghty 23,336,364 9,772,133 13,057,844 Steven Hyman, M.D. 30,442,488 2,666,009 13,057,844 Alfred Sandrock, M.D., Ph.D. 31,890,428 1,218,069 13,057,844”
Voyager Therapeutics, Inc. reported first quarter 2026 results: revenue $2.6 million, net income $27.9 million.
“Collaboration revenue was $2.6 million for the three months ended March 31, 2026, compared to $6.5 million for the first quarter of 2025.”
Voyager Therapeutics, Inc. reported the year ended December 31, 2025 results: revenue $40.4 million, net income $119.7 million.
“● Collaboration Revenues: Collaboration revenue was $15.3 million for the three months ended December 31, 2025, compared to $6.3 million for the same period in 2024 , and $40.4 million for the year ended December 31, 2025, compared to $80.0 million for the same period in 2024. The increase for the three months ended December 31, 2025, was primarily due to”
Voyager Therapeutics, Inc. reported the three months ended December 31, 2025 results: revenue $15.3 million, net income $27.4 million.
“intends to initiate a clinical trial with NBIB-‘223 for FA, pending successful FDA IND clearance Financial Results ● Collaboration Revenues: Collaboration revenue was $15.3 million for the three months ended December 31, 2025, compared to $6.3 million for the same period in 2024 , and $40.4 million for the year ended December 31, 2025, compared to $80.0”
Nathan Jorgensen was appointed as Chief Financial Officer at Voyager Therapeutics, Inc..
“On June 11, 2024, Voyager Therapeutics, Inc. (the “Company”) and Nathan Jorgensen entered into an employment agreement (the “Jorgensen Agreement”), pursuant to which Dr. Jorgensen agreed to serve as the Chief Financial Officer of the Company, with his employment to commence no later than July 8, 2024”
Voyager Therapeutics, Inc. reported first quarter 2024 results: revenue $19.5 million, net income $11.3 million.
“INDs for the GBA1 and Friedreich’s Ataxia gene therapy programs in 2025. First Quarter 2024 Financial Results ● Collaboration Revenues: Voyager had collaboration revenue of $19.5 million for the first quarter of 2024, compared to $150.5 million for the same period in 2023. The decrease was primarily due to the first quarter 2023 recognition of $69.5 million from”
Voyager Therapeutics, Inc. reported Q4 2023 results: revenue $90.1 million, net income $56.4 million.
“Voyager had collaboration revenue of $90.1 million for the fourth quarter of 2023”
Voyager Therapeutics, Inc. entered into Underwriting Agreement with Citigroup Global Markets Inc. and Guggenheim Securities, LLC valued at 7,777,778 shares of common stock at $9.00 per share; pre-funded warrants for up to 3,333,333 shares (effective 2024-01-04).
“On January 4, 2024, Voyager Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 7,777,778 shares (the “Firm Stock”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and, in lieu of Common Stock to certain investors, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 3,333,333 shares of Common Stock (the “Warrant Stock”).”
Voyager Therapeutics, Inc. entered into License and Collaboration Agreement with Novartis Pharma AG valued at $80 million (effective 2023-12-28).
“On December 28, 2023 (the “Effective Date”), Voyager Therapeutics, Inc. (the “Company”) entered into a License and Collaboration Agreement (the “Collaboration Agreement”) with Novartis Pharma AG (“Novartis”)”
Voyager Therapeutics, Inc. updated its mid-2025 guidance (reaffirmed).
“We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine collaborations and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into mid-2025 .”
Voyager Therapeutics, Inc. amended lease obligation of Annual base rent of approximately $4.9 million increasing annually by approximately 3%; total commitment of ~$2.3 millio with LS 75 Hayden, LLC at Not applicable (lease) maturing January 31, 2031.
“mendment”) to its existing lease agreement with LS 75 Hayden, LLC, as successor in interest to HCP/King 75 Hayden LLC (the “Landlord”),”
Voyager Therapeutics, Inc. amended Lease Agreement with LS 75 Hayden, LLC (effective 2023-08-11).
“On August 11, 2023, Voyager Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a first amendment (the “First Amendment”) to its existing lease agreement with LS 75 Hayden, LLC, as successor in interest to HCP/King 75 Hayden LLC (the “Landlord”), dated March 16, 2020 (the “Lease Agreement”)”
Voyager Therapeutics, Inc. reported the six months ended June 30, 2023 results: revenue $155.3 million, net income Net income was $101.8 million.
“Voyager had collaboration revenue of $155.3 million for the six months ended June 30, 2023 period”
Voyager Therapeutics, Inc. reported the second quarter of 2023 results: revenue $4.9 million, net income Net loss was $22.2 million.
“Voyager had collaboration revenue of $4.9 million for the second quarter of 2023”
Voyager Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-06 meeting.
“Voyager’s stockholders ratified the appointment of Ernst & Young LLP as Voyager’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain Broker Non-Votes 29,090,596 32,521 2,864 —”
Voyager Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2023-06-06 meeting.
“Voyager’s stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager’s named executive officers. The results of the stockholders’ vote with respect to such proposal were as follows: For Against Abstain Broker Non-Votes 20,162,995 523,972 33,553 8,405,461”
Voyager Therapeutics, Inc. shareholders approved Election of Class II directors at the 2023-06-06 meeting.
“Voyager’s stockholders elected Steven Hyman, M.D., James A. Geraghty, and Alfred Sandrock, M.D., Ph.D., each to serve as a Class II director until the 2026 Annual Meeting of Stockholders and until his successor has been duly elected and qualified, subject to his earlier death, resignation, or removal. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Steven Hyman, M.D. 20,552,674 167,846 8,405,461 James A. Geraghty 16,613,243 4,107,277 8,405,461 Alfred Sandrock, M.D., Ph.D. 20,551,414 169,106 8,405,461”
Voyager Therapeutics, Inc. reported first quarter 2023 results: revenue $150.5 million, net income $124.0 million.
“In January 2023, Grace E. Colón, Ph.D., also joined the Board of Directors. First Quarter 2023 Financial Results ● Collaboration Revenues: Voyager had collaboration revenue of $150.5 million for the first quarter of 2023, compared to $0.7 million for the same period in 2022. The increase was primarily due to revenue recognized during the first quarter of 2023 on the”
George Scangos was appointed as director at Voyager Therapeutics, Inc..
“On May 6, 2023, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed George Scangos, Ph.D. as a director of the Company and as a member of the Science and Technology Committee of the Board, effective May 9, 2023.”
Jude Onyia, Ph.D. was appointed as director at Voyager Therapeutics, Inc..
“the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), approved the appointment of Jude Onyia, Ph.D., to serve as a director of the Company, contingent upon and effective as of the closing”
Robert W. Hesslein resigned as Senior Vice President and General Counsel at Voyager Therapeutics, Inc..
“Mr. Hesslein resigned from his position of Senior Vice President and General Counsel and from any and all other positions he holds as an officer or employee of the Company or an officer, employee or director of any of its subsidiaries, effective on April 28, 2023”
Voyager Therapeutics, Inc. entered into Collaboration and License Agreement with Neurocrine Biosciences, Inc. (effective 2023-01-08).
“On January 8, 2023 (the “Agreement Date”), Voyager Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Neurocrine Biosciences, Inc. (“Neurocrine”) for the research, development, manufacture and commercialization of gene therapy products directed to the gene that encodes glucosylceramidase beta 1 (“GBA1”)”
Grace E. Colón was appointed as director at Voyager Therapeutics, Inc..
“appointed Grace E. Colón, Ph.D. as a director of the Company and as a member of the Compensation Committee of the Board, effective January 1, 2023.”
Peter P. Pfreundschuh was appointed as Chief Financial Officer at Voyager Therapeutics, Inc..
“pursuant to which Mr. Pfreundschuh agreed to serve as the Chief Financial Officer of the Company, with the first date of employment to commence on September 19, 2022”
Catherine J. Mackey, Ph.D. was appointed as director at Voyager Therapeutics, Inc..
“On July 27, 2022, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Catherine J. Mackey, Ph.D. as a director of the Company and as a member of both the Audit Committee and the Science and Technology Committee of the Board, effective August 15, 2022.”
Glenn Pierce resigned as Interim Chief Scientific Officer at Voyager Therapeutics, Inc..
“On June 2, 2022, Glenn Pierce, M.D., Ph.D. provided notice to Voyager Therapeutics, Inc. (“Voyager”) of his resignation as Interim Chief Scientific Officer, effective immediately (the “Pierce Transition”).”
Steven Paul, M.D. departed as Director at Voyager Therapeutics, Inc..
“Mark Levin and Steven Paul, M.D. each requested not to be nominated for re-election to the Board when his current term expires at the Company’s 2022 annual meeting of stockholders.”
Mark Levin departed as Director at Voyager Therapeutics, Inc..
“Mark Levin and Steven Paul, M.D. each requested not to be nominated for re-election to the Board when his current term expires at the Company’s 2022 annual meeting of stockholders.”
Alfred Sandrock was appointed as President and Chief Executive Officer at Voyager Therapeutics, Inc..
“Appointment of Alfred Sandrock, M.D., Ph.D. as President and Chief Executive Officer”
Alfred Sandrock, M.D., Ph.D. was appointed as director at Voyager Therapeutics, Inc..
“appointed Alfred Sandrock, M.D., Ph.D. as a director of the Company and as a member of both the Executive Committee and the Science and Technology Committee of the Board, effective February 7, 2022.”
Julie Burek was appointed as principal financial officer and principal accounting officer at Voyager Therapeutics, Inc..
“the board of directors of the Company (the "Board") has appointed Julie Burek to assume the roles of principal financial officer and principal accounting officer of the Company, effective as of the Effective Date.”
Allison Dorval resigned as Chief Financial Officer at Voyager Therapeutics, Inc..
“Allison Dorval notified Voyager Therapeutics, Inc. (the "Company") of her resignation as Chief Financial Officer of the Company, effective November 26, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.